-
Overview of Key Updates in the 2024 NCCN Guidelines for Acute Myeloid Leukemia (AML) – First Edition
The latest 2024 NCCN guidelines for Acute Myeloid Leukemia (AML) have been published, presenting significant revisions compared to the 2023, Version 6 update. The new edition brings substantial updates in areas such as intensive induction therapy for AML, post-induction follow-up and reinduction therapy, consolidation, and maintenance treatments.
-
IHPBA President Interview | Professor René Adam: Exploring Innovative Treatments for CRLM
October 21-27, 2024, Wuhan, at the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (IHPBA), we interviewed Professor René Adam, the current President of the IHPBA and a famous surgeon at AP-HP Paul Brousse Hospital in Paris, France, to share his research explorations on the use of liver transplantation combined with…
-
ESMO 2024 | Dr. Dingwei Ye Presents Promising Data on BL-B01D1 for Advanced Urothelial Carcinoma
At the ESMO 2024 Congress in Barcelona, Dr. Dingwei Ye from Fudan University Shanghai Cancer Center presented findings from a phase 2 study on BL-B01D1, a novel EGFR and HER3…
-
Dr. Zhiyong Ma: Individualized and Duration-Specific Consolidation Therapy for Lung Cancer Patients
The “Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2024 Edition)” was recently released under the guidance of Academician Jinming Yu from Shandong Cancer Hospital, Professor Ying Cheng from Jilin Cancer Hospital, and Professor Liang’an Chen from the Chinese PLA General Hospital. This consensus provides evidence and guidance for the application of…
-
ILCA 2024丨Dr. Stephen L. Chan Shares EMERALD-1 Post-Hoc Analysis on Safety and Efficacy Across Different Treatment Phases and Liver Function Levels
The Phase III EMERALD-1 study has shown that for patients with unresectable intermediate to advanced hepatocellular carcinoma (HCC), the combination of durvalumab, bevacizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival (PFS) compared to TACE alone. At the 2024 International Liver Cancer Association (ILCA) conference, Dr. Stephen L. Chan from the Faculty of Medicine at…
-
Balancing Toxicity and Efficacy: How Does Combining ADCs with Other Therapies Impact NSCLC Treatment Prospects?
For advanced non-small cell lung cancer (NSCLC), treatment strategies typically include platinum-based doublet chemotherapy, immunotherapy, and targeted therapy, with specific methods determined by molecular biomarker testing. Current unmet medical needs for advanced NSCLC patients include a lack of new treatment options following the failure of immunotherapy combinations, resistance to targeted therapies, and strategies to improve…
-
Optimal Treatment for Resectable NSCLC: Should All Patients Receive Perioperative Immunotherapy?
Recently, several immune checkpoint inhibitor (ICI) regimens have gained regulatory approval for neoadjuvant, adjuvant, and perioperative treatment, transforming the treatment landscape for patients with resectable non-small cell lung cancer (NSCLC). Based on the KEYNOTE-671 study, the perioperative pembrolizumab regimen has been approved for resectable NSCLC in stages II, IIIA, or IIIB (T3-4N2). Is this now…
Connecting Medical Expertise through Media
